CEMI - Chembio Diagnostics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.52
-0.18 (-3.16%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.70
Open5.45
Bid0.00 x 1400
Ask0.00 x 800
Day's Range5.52 - 5.80
52 Week Range4.39 - 8.95
Volume19,294
Avg. Volume43,996
Market Cap96.962M
Beta (3Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-0.73
Earnings DateAug 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.25
Trade prices are not sourced from all markets
  • GlobeNewswire

    Chembio Diagnostics Receives WHO Prequalification Approval for Malaysia Facility

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its manufacturing facility in Malaysia has been qualified by the World Health Organization (WHO) Prequalification program to produce Stat-Pak HIV 1/2 tests. The WHO Prequalification of In Vitro Diagnostics (IVD) is a comprehensive assessment of individual IVDs through a standardized assessment process that includes inspection of the manufacturing site, review of a product dossier, performance evaluation including operational characteristics, and labelling review.

  • Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) CEO Salary Justified?
    Simply Wall St.

    Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) CEO Salary Justified?

    John Sperzel has been the CEO of Chembio Diagnostics, Inc. (NASDAQ:CEMI) since 2014. This report will, first, examine...

  • Chembio Diagnostics (NASDAQ:CEMI) Has Debt But No Earnings; Should You Worry?
    Simply Wall St.

    Chembio Diagnostics (NASDAQ:CEMI) Has Debt But No Earnings; Should You Worry?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • GlobeNewswire

    Chembio Diagnostics Announces $20 Million Term Loan with Perceptive Advisors

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the closing of a $20 million term loan with an affiliate of Perceptive Advisors, one of the world’s leading healthcare-focused investment firms. “We are excited to have received this capital from Perceptive Advisors, a prestigious and well-regarded healthcare investment firm.” said John Sperzel, Chembio’s Chief Executive Officer.

  • GlobeNewswire

    Chembio Diagnostics to Participate in Upcoming Investor Conferences

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the company plans to participate in two upcoming investor conferences. Management is scheduled to participate in the Dougherty & Company Institutional Investor Conference in Minneapolis, Minnesota on Thursday, September 5, 2019. Management is also scheduled to present at the Janney Healthcare Conference in New York, New York on Monday, September 9, 2019 at 12:35 pm ET.

  • Thomson Reuters StreetEvents

    Edited Transcript of CEMI earnings conference call or presentation 6-Aug-19 8:30pm GMT

    Q2 2019 Chembio Diagnostics Inc Earnings Call

  • What Kind Of Shareholder Owns Most Chembio Diagnostics, Inc. (NASDAQ:CEMI) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most Chembio Diagnostics, Inc. (NASDAQ:CEMI) Stock?

    The big shareholder groups in Chembio Diagnostics, Inc. (NASDAQ:CEMI) have power over the company. Large companies...

  • GlobeNewswire

    Chembio Diagnostics Reports Second Quarter 2019 Financial Results

    MEDFORD, N.Y., Aug. 06, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • GlobeNewswire

    Chembio Diagnostics to Participate in the Canaccord Genuity Growth Conference

    MEDFORD, N.Y., July 24, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the.

  • GlobeNewswire

    Chembio Diagnostics to Report Second Quarter 2019 Financial Results on August 6, 2019

    MEDFORD, N.Y., July 24, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it.

  • GlobeNewswire

    Chembio Diagnostics and Takeda Pharmaceutical Company Enter Collaboration to Develop Point-of-Care Diagnostic Test

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care (POC) diagnostics company focused on infectious diseases, today announced that it has entered into a collaboration with Shire Human Genetic Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, a global pharmaceutical company, to develop a novel POC diagnostic test to detect an undisclosed biomarker. Under terms of the agreement, Chembio will receive funding from Takeda, subject to satisfying certain milestones, to develop a quantitative POC test utilizing Chembio’s patented DPP platform and hand-held optical analyzer. The development of the POC test will build upon Takeda’s technical research on a unique set of biomarkers and is expected to provide quantitative results in approximately 15 minutes from a small 10µL drop of fingerstick blood.

  • Should You Be Concerned About Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Historical Volatility?

    Anyone researching Chembio Diagnostics, Inc. (NASDAQ:CEMI) might want to consider the historical volatility of the...

  • GlobeNewswire

    Chembio Diagnostics Receives CE Mark for its Point-of-Care Multiplex Test for Zika, Dengue and Chikungunya

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that is has obtained a CE mark for its DPP Zika/Dengue/Chikungunya multiplex test system. Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small (10µL) drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s handheld DPP Micro Reader.

  • GlobeNewswire

    Chembio Diagnostics Announces Approval of Dengue Point-of-Care Test by Brazil’s Health Regulatory Agency

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos, a Brazilian government agency and supplier of diagnostic products to Brazil’s Ministry of Health. Chembio’s DPP Dengue test allows simultaneous and discrete detection of antibodies against all four dengue serotypes for both active infection by dengue virus (IgM) and prior exposure to the dengue virus (IgG), which is important for both treatment and surveillance.

  • Thomson Reuters StreetEvents

    Edited Transcript of CEMI earnings conference call or presentation 1-May-19 8:30pm GMT

    Q1 2019 Chembio Diagnostics Inc Earnings Call

  • GlobeNewswire

    Chembio Diagnostics Reports First Quarter 2019 Financial Results

    MEDFORD, N.Y., May 01, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • Introducing Chembio Diagnostics (NASDAQ:CEMI), The Stock That Zoomed 142% In The Last Five Years
    Simply Wall St.

    Introducing Chembio Diagnostics (NASDAQ:CEMI), The Stock That Zoomed 142% In The Last Five Years

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all...

  • GlobeNewswire

    Chembio Diagnostics to Report First Quarter 2019 Financial Results on May 1, 2019

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2019 after the close of trading on Wednesday, May 1, 2019. Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

  • GlobeNewswire

    Chembio Diagnostics Announces Approval of Zika, Dengue and Chikungunya Point-of-Care Multiplex Test by Brazil’s Health Regulatory Agency

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Zika/Dengue/Chikungunya System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos/Fiocruz. Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small (10µL) drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s handheld DPP Micro Reader.

  • Thomson Reuters StreetEvents

    Edited Transcript of CEMI earnings conference call or presentation 7-Mar-19 9:30pm GMT

    Q4 2018 Chembio Diagnostics Inc Earnings Call

  • GlobeNewswire

    Chembio Diagnostics Announces Agreement with Perseus Science to Advance Point-of-Care Concussion Test

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the company has entered into an agreement with Perseus Science Group LLC, to advance the development of a diagnostic test for mild traumatic brain injury (TBI), or concussion. This agreement builds on previous agreements between the two firms that resulted in the completion of technical feasibility to detect Perseus’ patented biomarker. Under terms of this agreement, Chembio will receive funding from Perseus, subject to satisfying certain milestones, to advance the development of a quantitative point-of-care test for concussion, combining Chembio's proprietary DPP platform with Perseus’ biomarker.

  • Zacks Small Cap Research

    CEMI: Revenue, margin guidance and historical context indicates this could be opportune entry point

    Chembio (CEMI) reported financial results for their fourth quarter ending December 31st and provided an operating update. Product sales were just about dead-on with our estimate and up 16% yoy to $5.6M. Total revenue jumped 27% to $7.6M, aided by a very healthy $1.7M in R&D contracts, milestones and grant revenue – which is the greatest quarterly revenue from this category in company history.

  • GuruFocus.com

    Chembio Diagnostics Inc (CEMI) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Chembio Diagnostics Inc develops, manufactures, and commercializes point of care diagnostic tests that detect infectious diseases. Warning! GuruFocus has detected 4 Warning Signs with CEMI. For the last quarter Chembio Diagnostics Inc reported a revenue of $7.60 million, compared with the revenue of $5.99 million during the same period a year ago.

  • Have Insiders Been Buying Chembio Diagnostics, Inc. (NASDAQ:CEMI) Shares?
    Simply Wall St.

    Have Insiders Been Buying Chembio Diagnostics, Inc. (NASDAQ:CEMI) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales haveRead More...

  • GlobeNewswire

    Chembio Diagnostics Reports Fourth Quarter and Full Year 2018 Financial Results

    MEDFORD, N.Y., March 07, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.